Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE;OMIM 603041) is a rare autosomal recessive disease caused by mutations in the TYMP gene encoding thymidine phosphorylase (TP;E.C, 2.4.2.4). Seventeen years ago, we described MNGIE as a clinically distinct disorder characterized by extraocular muscle weakness causing ptosis and ophthalmoplegia, peripheral neuropathy, gastrointestinal dysmotility causing severe cachexia, leukoencephalopathy, and mitochondrial abnormalities including multiple deletions of mitochondrial DNA (mtDNA) in skeletal muscle. The disease is relentlessly progressive and fatal with an average age-at-onset of 19-years-old and an average age-at-death of 37-years-old. We have mapped the disease locus to chromosome 22q13.32-tel, identified the causative gene[3,4], characterized the molecular pathogenesis[5-11] and generated a mouse model [12] Although the prevalence of MNGIE is unknown, at least 140 cases have been identified in diverse ethnic groups. Our studies of MNGIE have demonstrated that TYMP mutations cause severe loss of TP activity that dramatically elevates tissue and plasma levels of the pyrimidine nucleosides thymidine (Thd) and deoxyuridine (dUrd), which produce deoxynucleoside triphosphate (dNTP) pool imbalances that, in turn, produce instability of mitochondrial DNA (mtDNA). The mtDNA instability manifests as somatic multiple deletions, depletion, and site-specific point mutations. Based on these findings, we have hypothesized that TP enzyme replacement via allogeneic hematopoietic stem cell transplantation (AHSCT) will be therapeutic by virtue of eliminating the toxic metabolites, Thd and dUrd, and restoring balanced dNTP pools. In fact, in this U54 application, we are proposing the AHSCT for MNGIE International Collaborative Trial (AMICT) to assess safety and efficacy of AHSCT for MNGIE using biomarkers as the primary and secondary outcome measures. Because therapy is being tested for MNGIE, it is imperative to document the natural history of this disease in order to develop meaningful clinical measures for therapeutic trials. Thus, the overall purpose of this study of MNGIE is to define its natural history and to identify optimal outcome measure that correlate with disease progression and can be used for the assessment of new therapies that seek FDA approval.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54NS078059-01
Application #
8293863
Study Section
Special Emphasis Panel (ZNS1-SRB-S (52))
Project Start
Project End
Budget Start
2011-09-30
Budget End
2012-08-31
Support Year
1
Fiscal Year
2011
Total Cost
$152,079
Indirect Cost
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Hirano, Michio; Emmanuele, Valentina; Quinzii, Catarina M (2018) Emerging therapies for mitochondrial diseases. Essays Biochem 62:467-481
Raghavan, Neha S; Brickman, Adam M; Andrews, Howard et al. (2018) Whole-exome sequencing in 20,197 persons for rare variants in Alzheimer's disease. Ann Clin Transl Neurol 5:832-842
Barca, Emanuele; Ganetzky, Rebecca D; Potluri, Prasanth et al. (2018) USMG5 Ashkenazi Jewish founder mutation impairs mitochondrial complex V dimerization and ATP synthesis. Hum Mol Genet 27:3305-3312
Shen, Lishuang; Attimonelli, Marcella; Bai, Renkui et al. (2018) MSeqDR mvTool: A mitochondrial DNA Web and API resource for comprehensive variant annotation, universal nomenclature collation, and reference genome conversion. Hum Mutat 39:806-810
Garone, Caterina; Taylor, Robert W; Nascimento, Andrés et al. (2018) Retrospective natural history of thymidine kinase 2 deficiency. J Med Genet 55:515-521
Winawer, Melodie R; Griffin, Nicole G; Samanamud, Jorge et al. (2018) Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy. Ann Neurol 83:1133-1146
Zolkipli-Cunningham, Zarazuela; Xiao, Rui; Stoddart, Amy et al. (2018) Mitochondrial disease patient motivations and barriers to participate in clinical trials. PLoS One 13:e0197513
Al-Gadi, Iman S; Haas, Richard H; Falk, Marni J et al. (2018) Endocrine Disorders in Primary Mitochondrial Disease. J Endocr Soc 2:361-373
Mancuso, Michelangelo; McFarland, Robert; Klopstock, Thomas et al. (2017) International Workshop:: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16-18 November 2016, Rome, Italy. Neuromuscul Disord 27:1126-1137
Bedoyan, Jirair K; Yang, Samuel P; Ferdinandusse, Sacha et al. (2017) Lethal neonatal case and review of primary short-chain enoyl-CoA hydratase (SCEH) deficiency associated with secondary lymphocyte pyruvate dehydrogenase complex (PDC) deficiency. Mol Genet Metab 120:342-349

Showing the most recent 10 out of 49 publications